All In Biotech

Drug Trial Radar · NCT01197534

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs

Last checked: Nov 20, 2026Latest source record: Apr 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 913 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

913

Actual

Start

Sep 2010

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.

Conditions

  • Rheumatoid Arthritis

Interventions

  • fostamatinibDrug

    fostamatinib 100 mg twice daily

  • fostamatinibDrug

    fostamatinib 100 mg twice daily/ 150 mg once daily

  • placebo, fostamatinibDrug

    Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and PlaceboTime frame: 24 weeks

Locations

149 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Mesa, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Huntington Beach, California

  • Research Site

    Torrance, California

  • Research Site

    Trumbull, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Boca Raton, Florida

  • Research Site

    Brandon, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Venice, Florida

  • Research Site

    Zephyrhills, Florida

  • Research Site

    Canton, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Macon, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    South Bend, Indiana

  • Research Site

    Elizabethtown, Kentucky

  • Research Site

    Crofton, Maryland

  • Research Site

    Cumberland, Maryland

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Flowood, Mississippi

  • Research Site

    St Louis, Missouri

  • Research Site

    Kalispell, Montana

  • Research Site

    Omaha, Nebraska

  • Research Site

    Manalapan, New Jersey

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    Rochester, New York

  • Research Site

    Roslyn, New York

  • Research Site

    Syracuse, New York

  • Research Site

    Charlotte, North Carolina

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.